Scynexis reports Q3 EPS (4c), consensus (15c)

Reports Q3 revenue ($600,000), consensus $5.89M. During Q3 SCYNEXIS recognized a non-cash gain of $7.5M. Cash, cash equivalents and investments totaled $105.2M on September 30, compared to $73.5M on December 31, 2022. “We faced unexpected challenges associated with the recent BREXAFEMME recall and the clinical hold placed on the MARIO trial this quarter,” said David Angulo, President and CEO of SCYNEXIS. “While options for resolution of these issues are being evaluated we continue making progress towards data analysis for recently completed clinical studies. Our solid cash position has allowed us to advance the development of our next generation triterpenoid antifungal ‘SCY-247’ and continue to seek to maximize shareholder value while avoiding the volatile capital markets.”